Compass Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Compass Therapeutics, Inc. (NASDAQ: CMPX) on February 24, 2023, reporting an event that occurred on February 20, 2023. The Company is a biopharmaceutical firm focused on developing therapies for rare genetic diseases.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The primary material change reported is the departure of a member of the Board of Directors. On February 20, 2023, David Wurzer resigned from the Board and all committees thereof, effective immediately. The resignation was attributed to personal family reasons and was not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No new risks or contingencies were disclosed in this specific report other than the standard corporate governance change.
Key Facts for Investor Verification
- David Wurzer has resigned from the Board of Directors effective February 20, 2023.
- The resignation was voluntary and due to personal family reasons.
- There is no indication of disagreement between the departing director and the Company.
- Investors should verify if the Board has initiated a search for a replacement director to maintain quorum and committee composition.